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Background: Early cognitive impairment in Alzheimer Disease (AD) is thought to result from the dysfunctional
effect of amyloid beta (Aβ) oligomers targeting the synapses. Some individuals, however, escape cognitive decline
despite the presence of the neuropathologic features of AD (Aβ plaques and neurofibrillary tangles). We term this
group Non-Demented with AD Neuropathology or NDAN. The present study illustrates one putative resistance
mechanism involved in NDAN cases which may suggest targets for the effective treatment of AD.
Results: Here we describe the localization of Aβ oligomers at the postsynapse in hippocampi from AD cases.
Notably, however, we also found that while present in soluble fractions, Aβ oligomers are absent from hippocampal
postsynapses in NDAN cases. In addition, levels of phosphorylated (active) CREB, a transcription factor important for
synaptic plasticity, are normal in NDAN individuals, suggesting that their synapses are functionally intact. Analysis of
Zn2+ showed that levels were increased in both soluble fractions and synaptic vesicles in AD hippocampi, paralleled
by a decrease of expression of the synaptic vesicle Zn2+ transporter, ZnT3. Conversely, in NDAN individuals, levels of
Zn2+ in soluble fractions were significantly lower than in AD, whereas in synaptic vesicles the levels of Zn2+ were
similar to AD, but accompanied by preserved expression of the ZnT3.
Conclusions: Taken together, these data illustrate that despite substantial AD neuropathology, Aβ oligomers, and
increased synaptic vesicle Zn2+, susceptible brain tissue in these aged NDAN individuals features, as compared to
symptomatic AD subjects, significantly lower total Zn2+ levels and no association of Aβ oligomers with the
postsynapse, which collectively may promote the maintenance of intact cognitive function.
Keywords: Aβ oligomers, Alzheimer’s disease, hippocampus, asymptomatic, zinc, synaptic vesicleBackground
There is no effective treatment currently available for
Alzheimer’s disease (AD), the most common and severe
age-related dementia, and the number of cases diag-
nosed each year is rising [1]. New ideas and effective
therapeutic targets are therefore urgently needed. Neu-
ropathologically, AD is characterized by the presence in
the central nervous system of extracellular senile plaques
primarily formed by deposits of large fibrillar aggregates* Correspondence: gtaglial@utmb.edu
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reproduction in any medium, provided the orof the amyloid beta (Aβ) protein and by intracellular
neurofibrillary tangles (NFT) formed by hyper-phos-
phorylated tau protein [2,3].
However, aged individuals with abundant Aβ plaques
and NFT who are nonetheless cognitively intact have
also been described [4-8]. Notably, the National Institute
of Health/National Institute on Aging and the Alzhei-
mer’s Association have recently included such indivi-
duals in their joint official guidelines for
neuropathologic assessment of AD and classified them
as individuals who have AD neuropathologic changes in
the absence of cognitive impairment [9]. It is currentlyral Ltd This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mented with Alzheimer’s Neuropathology (NDAN), are
resistant to the clinical manifestations of AD despite a
significant burden of pathological lesions equivalent to
what is normally found in comparably aged subjects with
established AD. In one study, NDAN individuals have
been found to have larger hippocampal and total brain
volume [6], suggesting cognitive reserve may play a role,
but evidence remains incomplete. Nonetheless, the now
recognized existence of NDAN individuals suggests that
there are mechanisms by which the aging human brain
may cope with cognitive dysfunction brought about by
Aβ and NFT’s; and determining the protective molecular
mechanisms involved in these resistant individuals could
lead to the identification of novel targets for the devel-
opment of effective therapeutic approaches [9].
In recent years, the focus of research on the toxic role
of Aβ has shifted from the Aβ fibrils that comprise the
insoluble plaques, to the smaller, soluble oligomeric Aβ
aggregates that precede plaque formation. These oligo-
mers are considered to be the most toxic Aβ species
[10,11]. In experiments using cultured cells, Aβ oligo-
mers prepared from synthetic peptides are cytotoxic
whereas Aβ monomers or fibrils are relatively innocuous
[12,13]. Furthermore, Aβ oligomers of human and mur-
ine origin have been shown to induce memory defi-
cits when injected intracerebroventricularly in rodents
[14-16] and to localize to synapses [17,18], where they
affect the protein composition of the postsynaptic density
(PSD) [17,19] and impair synaptic plasticity [16,20]. The
downstream effects of Aβ oligomer synaptotoxicity in-
clude disruption of intracellular Ca2+ homeostasis [13]
and subsequent calcineurin-dependent dephosphoryla-
tion of NFAT [21] and key functional synaptic proteins
such as the cAMP response element binding (CREB) pro-
tein [12], a transcription factor regulating the transcrip-
tion of genes involved in synapse maintenance and
formation [22].
Zn2+, a transition metal dysregulated in AD [23,24],
has been shown to stabilize Aβ oligomers [25] and target
them to the postsynapse [26]. Zn2+ is an important neu-
romodulator involved in many processes in the brain.
Many studies have found alterations in Zn2+ levels in the
AD brain, with most reporting an increase in its concen-
tration [27-29]. In addition, the mRNA and protein ex-
pression of the Zn2+ transporter 3 (ZnT3) and the Zn2+
binding protein, metallothionein 3, are decreased in AD
[30-33]. This collective evidence indicates that the regu-
lation of Zn2+ is unbalanced in the AD brain and sug-
gests a role of Zn2+ in AD pathogenesis.
Zn2+ can be taken up into presynaptic terminals and
then packaged into synaptic vesicles along with glutam-
ate by the vesicle-specific ZnT3 [34]. During synaptic
transmission, Zn2+ and glutamate are co-released intothe synaptic cleft and interact with postsynaptic proteins
[35,36]. Zn2+ is essential for the modulation of calcium
channels, AMPA receptors, and NMDA receptors [37-39].
Therefore, changes in levels of synaptic Zn2+ have the po-
tential to alter synaptic transmission. Furthermore, Zn2+
can coordinate with the N-terminal region of Aβ most
likely by binding with three histidines and an oxygen side
chain [40-42]. This induces conformational changes and
facilitates intermolecular interactions conducive to oligo-
mer formation [43-45]. Indeed, the coordination of Zn2+
interferes with Aβ aggregation process, preventing fibril
assembly and favoring the formation of stable oligomers
[25]. These molecular events are induced with transient
Zn2+ pulses, similar to those that occur during synaptic
release, which has the potential of stabilizing ambient, in-
ter-synaptic oligomeric Aβ [25]. In addition to stabilizing
oligomers, Zn2+ enhances the synaptic association of Aβ
as synaptic targeting of Aβ is decreased by Zn2+ chelation
or in primary neuronal cell cultures from ZnT3 knockout
mice that have virtually no synaptic Zn2+ [26]. This col-
lective evidence highlights the role of releasable Zn2+in
both the toxicity and targeting of Aβ oligomers within the
synapse.
On these bases, the cognitive integrity of NDAN indi-
viduals suggests a lack of synaptic dysfunction that may
reflect resistance to the synaptotoxic effects of Aβ oligo-
mers and dysregulated Zn2+. The focus of the present
study was to investigate these features in the hippocam-
pus from cognitively-intact NDAN subjects as compared
to AD individuals who succumb to dementia. We per-
formed subcellular fractionations coupled with immuno-
blotting and graphite furnace-atomic absorption
spectrophotometry (GF-AAS) to measure Zn2+ along
with immunohistochemical analyses of human hippo-
campi to compare age-matched control and AD to
NDAN cases. We found substantial differences between
the AD and NDAN samples in terms of Aβ oligomer
presence at the PSD, integrity of synaptic proteins, and
Zn2+ regulation. These data suggest details about toxic
mechanism(s) in AD that initiate cognitive decline and
suggest therapies that target Zn2+ homeostasis in the




The neuropathological and clinical characteristics of the
cases used in this study are summarized in Table 1. The
details of the cognitive examination of the study subjects
have been reported previously [4,6,46] and neuropatho-
logical methods are detailed in the Methods section.
Groups were designated based on Braak and plaque
stages according to CERAD specifications and the Mini
Mental State Exam (MMSE) test scores as described in
Table 1 Characteristics of cases defined by
neuropathology and dementia status.
Diagnosis n Age (yrs)
(mean)






Control 13 84.8 8 F, 5 M 14.2 ± 3 1 1 29
AD 21 81 12 F, 8 M, 1NA 12.2 ± 2 6 3 9
NDAN 10 89.5 7 F, 3 M 10.7 ± 4 5 3 28
PMI: Postmortem interval; NA: data not available.
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0–2 and no more than sparse neuritic plaques and were
cognitively intact on annual neuropsychiatric testing, as
summarized by terminal MMSE scores >25. The AD
group had Braak scores of 6 and moderate to frequent
neuritic plaques with below normal MMSE scores (aver-
age of 9). The NDAN cases had Braak scores that ranged
from 4 to 6 and a range of neuritic plaque densities, but
typically with moderate densities of neuritic plaques.
The MMSE scores in this group were comparable to
those in age-matched normal individuals (>25) with an
average of 28. The postmortem interval (PMI) was
<24 h, except for two cases. Tissue morphology was well
preserved in all samples and there was no sign of protein
degradation in Western blots performed on protein
extracts from samples used in this study.
Immunohistochemical, neuropathological, and Aβ
assessments demonstrate the similarities between AD
and NDAN
The pathological analysis described above for AD and
NDAN cases confirmed that these two groups have a
comparable presence of Aβ plaques and NFTs, further
corroborating the notion that cognitive diversity between
AD and NDAN individuals could not be ascribed to dif-
ferent extents of these two AD-related neuropathological
features [5]. Figure 1 shows representative panels of the
immunohistochemical detection of Aβ and phosphory-
lated tau (Figure 1A) and Bielschowsky staining of amyl-
oid plaques and NFTs (Figure 1B) in the hippocampus
from representative cases used in the present study. Fur-
thermore, the levels of Aβ1-42 were equally increased in
NDAN and AD as determined by a solid phase sandwich
enzyme-linked immunosorbent assay (ELISA)
(Figure 1C).
In addition to soluble monomers, Aβ1-42 is normally
present in the affected human brain in structurally dis-
tinct aggregated forms, including large fibrils, which are
the main component of senile plaques and small soluble
oligomers, which are believed to be the most neurotoxic
Aβ species [47-49], We therefore first determined which
of these low molecular weight (LMW) Aβ oligomeric
species were present in the hippocampus of NDAN
cases as compared to AD cases. Western blot analysisrevealed that LMW Aβ species of ~4, 8, and 12 kDa
were detectable in soluble fractions from hippocampi of
both AD and NDAN cases (Figure 1D). Statistical ana-
lysis applied to densitometry values obtained following
this approach showed that the levels of LMW Aβ species
were significantly increased in both groups compared to
control (Figure 1E). Thus, the presence of LMW Aβ spe-
cies in the NDAN samples eliminates the possibility that
these individuals remain cognitively intact due to lack of
highly neurotoxic Aβ oligomers.
These data highlight the presence of comparable levels
of plaques, tangles, Aβ 1–42 levels, and LMW Aβ oligo-
mers between AD and NDAN.
Low molecular weight Aβ oligomers are highly associated
with the postsynaptic density in AD, but not NDAN cases
Aβ oligomers have been shown to accumulate at the
synapses where they induce dysfunctional changes that
impair synaptic integrity [18,20,49]. Therefore, to further
assess the localization of the LMW Aβ species detected
in the AD and NDAN brains, we performed a synaptic
fractionation that separates presynaptic and postsynaptic
fractions [50] and probed the postsynaptic fractions for
the presence of Aβ by Western blotting. Successful syn-
aptic fractionation of the brain tissues was confirmed by
probing the Western blots of the different fractions with
antibodies directed against pre- and postsynaptic mar-
kers as illustrated in Figure 2A. The fractionation was
successful for each group (age-matched control, AD, and
NDAN) as shown by the enrichment of PSD95 in the
PSD fraction (Figure 2B).
When blots were probed for Aβ, we found that LMW
Aβ species were highly concentrated in the postsynaptic
fractions from AD hippocampi, but completely absent
from aged-matched controls and NDAN cases
(Figure 2C). Densitometric analysis (Figure 2D) con-
firmed that LMW Aβ species were abundant at the PSD
isolated from AD hippocampi but absent (undetectable
above background) in NDAN cases. This corroborates
previous reports that Aβ selectively targets the PSD in
AD [17,51].
To confirm that the LMW Aβ species found at the
PSD from AD hippocampi were oligomers, an Aβ oligo-
mer-specific antibody, NU4, was utilized [52]. The repre-
sentative Western blot in Figure 2E demonstrates that
the low molecular Aβ species detected in AD samples
are indeed oligomers (particularly dimers and trimers, as
assessed by comparison to synthetic (Synt) Aβ oligo-
mers). On the other hand, neither dimeric nor trimeric
Aβ species were detectable in the NDAN samples, and
this was statistically confirmed by densitometric analysis
of the blots (Figure 2F). Interestingly, an Aβ tetrameric
species was present in the sample from all groups, in-
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Figure 1 Pathological signatures of AD occur in cognitively intact individuals (NDAN). (A) Immunohistochemical detection shows reactivity
for Aβ plaques (top row) and phosphorylated tau (bottom row) in the dentate gyrus of individuals classifed as control (Braak 1, Plaque 3, MMSE
30), AD (Braak 6, Plaque 1, MMSE 2), or NDAN (Braak 6, Plaque 1, MMSE 27). DAPI-containing mounting medium was used to visualize nuclei
(blue). 20x magnification, scale bar 100 μm. (B) Bielschowsky staining in the hippocampus of an NDAN individual shows plaques (thin arrows) and
neurofibrillary tangles (thick arrows). (C) An ELISA shows increased Aβ1-42 in AD and NDAN hippocampi (n = 3 per group and asterisks (*) denote
values significantly higher than control with p< 0.05). (D) Representative Western blot of soluble hippocampal fractions (300 μg) from individual
cases probed with 6e10 shows that LMW Aβ species are present in both AD and NDAN. Densitometric analysis (F) of the major bands (monomer
at 4kD and dimer at 8.5kD) together shows that AD and NDAN cases are significantly different than control where the average optical density is
set at 100; the asterisks (*) denote statistical significance compared to the control value (p= 0.022, ANOVA); The Western blot shown is
representative of 9–10 individual cases assayed in each group and experiments were repeated 3 – 4 times.
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fested AD. These data demonstrate that while present in
the soluble fractions from both AD and NDAN cases,
Aβ oligomers are highly associated with the PSD only in
AD hippocampi, but are absent in the PSD prepared
from NDAN cases.
Expression of neuronal nuclear phosphorylated CREB is
preserved in NDAN hippocampi
Our previous studies have shown that one downstream
effect of Aβ oligomers dysfunctionally impacting synap-
ses is the decrease of active, phosphorylated CREB(pCREB), a transcription factor essential for synaptic
plasticity and memory function [12,16,53]. The cognitive
integrity of NDAN individuals suggests that synaptic
function is preserved in these individuals, which would
thus be consistent with the observed absence of Aβ at
the postsynapse. We therefore determined the expres-
sion of neuronal pCREB in each of the samples using
immunohistochemistry coupled to confocal microscopy
(Figure 3A) as an index of functional synaptic integrity.
When pCREB levels were quantified in granular neurons
of the dentate gyrus (DG) and in pyramidal neurons of


















































NDAN AD Control 















NDAN AD Control 
Case: 1 2 3 4 5 6 
NDAN AD Control 





Hom Syn PSD SV A B 
*  
*  
Figure 2 Synaptic fractionation demonstrates that low molecular weight Aβ oligomers associate with the PSD in AD but not NDAN
hippocampal specimens. (A) PSD95, a postsynaptic marker, and synaptophysin (Synphys), a presynaptic marker, were probed in the total
homogenate (Hom), synaptosomal (Syn), synaptic vesicles (SV), and postsynaptic density (PSD) fractions isolated from a frozen human
hippocampal specimen from a control, non-demented aged individual. Enrichment of the different fractions is shown by the presence/absence
of synaptic markers. The fractionation was successful for all case types (control, AD and NDAN) as shown by the purity of PSD fractions in (B). The
isolated PSD fraction from hippocampal samples from different cases from each group (aged matched controls, AD, and NDAN) were
immunoblotted together (representative blot shown; 40 μg protein each lane of a 10-20% tris-glycine gradient gel) and probed using 6e10 (C)
showing LMW Aβ only associates with AD samples. (D) Densitometric analyses of each of the Aβ species (monomer/dimer = 4–8.5 kD band,
trimer = 12 kD, and tetramer = 16 kD) demonstrates that all Aβ species are increased in AD. The results are expressed as the mean± SEM using
propagation of error and normalized with AD= 100%. The asterisk denotes the values significantly higher than control (monomer/dimer,
p= 0.012, trimer, p=< 0.001, and tetramer, p= 0.014; ANOVA; a Bonferroni correction was required for the monomer/dimer and trimer density
values). Hippocampus PSD fractions (80 μg) from age-matched controls, AD, and NDAN samples were immunoblotted and probed using NU4 (E).
A lane is included at the end showing synthetic (Synt) Aβ oligomers probed by NU4 for comparison. The densitometric analysis (F) of the dimer/
trimer band shows that AD cases are significantly higher than control and NDAN (both groups are essentially the same as background), while the
tetrameric species was not found to be significantly different across the groups (p= 0.67). The asterisk denotes significance compared to control,
p< 0.05, ANOVA. All Western blots shown are representative of 9–10 individual cases assayed in each group and experiments were repeated
3 – 4 times.
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fewer pCREB positive neurons in both cell populations
in subjects with AD. Conversely, despite the presence of
abundant Aβ and NFTs in the NDAN hippocampi, levels
of pCREB were similar to those of control cases. Levels
of pCREB were also measured by Western blot in total
homogenate fractions from each group (Additional File
1). Consistent with the immunohistochemistry results, we
found that there was a decrease in the AD samples, but
not NDAN, which however did not reach statistical sig-
nificance. This result is not completely unexpected if oneconsiders that total homogenate does contain proteins
contributed from both neurons and glial cells, both of
which express CREB, thus reducing the sensitivity of
Western blotting to detect changes in pCREB levels oc-
curring solely in neurons (as our immunohistochemistry
results seem to indicate). Notwithstanding this technical
limitation, direct observation by immunohistochemistry
and Western blot detection collectively indicate that
pCREB levels in hippocampal neurons are not reduced in
NDAN as compared to AD cases, thus suggesting that






























































Figure 3 Synaptic integrity is maintained in the NDAN hippocampus as suggested by preserved levels of neuronal nuclear pCREB. (A)
pCREB (red) and NeuN (green) expression was assessed in 10 μm sections of hippocampus. DAPI-containing mounting medium was used to
visualize nuclei (blue). pCREB immunoreactivity was decreased in the DG and CA3 neurons of AD hippocampi but not in NDAN cases (scale bar
50 μm). The number of neurons positive for nuclear pCREB was counted in the (B) DG and (C) CA3. Two images per region (DG and CA3) were
analyzed for each clinical case. The raw images were thresholded, and a blind counter quantified the number of neurons in the field of view, and
how many of these exhibited nuclear pCREB immunoreactivity. This value is expressed as the percentage of neurons that are pCREB
positive ± SEM (the asterisks denote statistical significance compared to controls at p≤ 0.05; ANOVA).
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altered in AD and NDAN
The exclusion of Aβ at the postsynapses in NDAN indi-
viduals suggests that mechanisms involved in the patho-
logical targeting of Aβ to synapses may be altered or
absent in these individuals. Among these, synaptic Zn2+
can coordinate with Aβ oligomers and target them to
the synapse where the oligomers can induce toxic effects
[26]. We therefore measured Zn2+ levels to determine if
alterations in Zn2+ concentration are associated with the
absence of Aβ oligomers at the postsynapse in NDAN
individuals. Soluble fractions from hippocampi were pro-
cessed as described in the methods and Zn2+ levels were
analyzed using GF-AAS. Our results show that the AD
specimens had significantly higher Zn2+ concentrations
than control (Figure 4A). Zn2+ levels in the NDAN tis-
sue were also higher than control, but significantly lower
than those observed in AD samples.
Zn2+ in the soluble fractions would include both pro-
tein-bound and releasable free Zn2+. The releasable Zn2+
stored into presynaptic vesicles and released duringsynaptic activity becomes available to coordinate with
proteins present at the synapse [54,55], including Aβ oli-
gomers. Therefore, to achieve a better assessment of the
levels of the releasable Zn2+ pool, synaptic vesicles were
isolated for analysis of Zn2+ content (Figure 4B). The
levels of Zn2+ in the synaptic vesicles were increased in
both AD and NDAN samples as compared to brain sam-
ples from age-matched control individuals.
The ZnT3 transports Zn2+ into synaptic vesicles and is
transcriptionally regulated by Zn2+ [54]. Previously,
mRNA and protein expression of this transporter was
found to be decreased in AD brain [30,32]. Immunoblots
probing for ZnT3 confirmed this finding and also
showed that ZnT3 expression in NDAN was maintained
at control levels (Figure 4C). Taken together these data
suggest that despite comparable levels of vesicular Zn2+,
but higher expression of the ZnT3 and lower Zn2+ in
the soluble fraction, the regulation of Zn2+ homeostasis
in NDAN individuals may be better preserved in com-
parison to AD cases, thus possibly reducing the Zn2+:



































































Figure 4 Differentially altered levels of total Zn2+, releasable
Zn2+, and ZnT3 expression in AD and NDAN hippocampus. (A)
Soluble hippocampal fractions were normalized for protein (500 μg),
digested with hydrogen peroxide and nitric acid, and analyzed using
a GF-AAS. Zn2+ levels in both AD and NDAN samples were
increased as compared to control, but NDAN Zn2+ levels were
significantly lower than AD levels. After a Bonferroni correction,
ANOVA results show p=< 0.001, n = 9–10 samples per group. (B)
Zn2+ analysis in synaptic vesicles shows that the Zn2+ concentration
in AD and NDAN is significantly higher than control (p=< 0.001
(after Bonferroni correction), n = 6–9 per group). (C) Representative
Western blot and densitometric analysis (D) of ZnT3 expression in
the hippocampus of individual cases shows a significant decrease in
AD, but not in NDAN samples, which is denoted by an asterisk (t-
test, p< 0.001 n = 6–9 per group, repeated 4 times).
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The main goal of the present study was to investigate
what molecular events are associated with the ability ofsome aged individuals to remain cognitively intact des-
pite the presence of increased Aβ1-42, Aβ plaques and
NFTs (Figrue 1). Our results show that NDAN indivi-
duals do have toxic Aβ oligomers, but that, at variance
with AD subjects, these oligomers do not associate with
the PSD. Along with the absence of oligomers at the
PSD, pCREB levels were sustained in NDAN, which sug-
gests that synaptic function is maintained. The total
Zn2+ levels in NDAN were lower than those in AD,
albeit still higher than control. On the other hand,
synaptic vesicle Zn2+ was increased in both AD and
NDAN, whereas ZnT3 expression was decreased in
AD but preserved in NDAN samples. Taken together,
and in light of the current literature evidence as
detailed below, these novel results suggest that Zn2+
regulation may be part of a mechanism that prevents
binding of Aβ oligomers to the postsynapse in NDAN
individuals, thus likely contributing to preservation of
synaptic and cognitive integrity (Figure 5).
The neuropathological and immunohistochemical ana-
lysis found that the extent and distribution of Aβ depos-
its and NFTs/hyper-phosphorylated tau in the
hippocampus is comparable between AD and NDAN
cases (Table 1 and Figure 1). Additionally, Aβ1-42 levels
are increased in NDAN similar to levels in AD and Aβ
species can be detected by Western blot analysis in total
protein extracts from both AD and NDAN hippocampi
(Figure 1D & E). The presence of LMW Aβ species
demonstrates that intact cognition could not be simply
ascribed to efficient, or off-pathway aggregation of Aβ
resulting in low levels or absence of Aβ oligomers.
When Aβ was assayed by Western blot in purified
PSD fractions the results showed a robust presence of
Aβ species in the AD cases, consistent with previous
studies [26,51]. However, there was a complete absence
of LMW Aβ species at the PSD isolated from NDAN
hippocampi (Figure 2C). These species were confirmed
to be Aβ oligomers using a LMW Aβ oligomer specific
antibody, NU4 (Figure 2E) [52]. Densitometric analysis
confirmed that at the PSD, the level of LMW Aβ of
NDAN was the same as control and indistinguishable
from background. However, the presence and level of an
apparent Aβ tetramer was surprisingly equal across the
groups. The postsynaptic presence of this Aβ tetrameric
species in the control samples suggests that it may not
be relevant to processes of cognitive loss in AD. That
LMW Aβ oligomers are present in the soluble fraction,
but not postsynaptic fractions of NDAN cases suggests
that the postsynaptic localization, rather than the mere
presence of the oligomers is key in initiating a cascade
of neurodysfunctional events eventually leading to cog-
nitive decline. Indeed, naturally occurring human LMW
Aβ oligomers, specifically dimers and trimers, have been
shown to be synaptotoxic [20,56] and the absence of
Figure 5 Aβ and Zn2+ differences in AD and NDAN hippocampal synapses. A schematic summarizing the findings presented in this report.
In AD there is increased Zn2+ in the soluble fraction compared to control and NDAN. However, both AD and NDAN have increased levels of Zn2+
in the synaptic vesicles (SV) which may actually reflect a storage compensatory mechanism to high Zn2+ levels. The reduction of ZnT3 in AD may
reflect a dysfunction of this compensatory mechanism, allowing for total Zn2+ levels to increase. Zn2+ is necessary for stabilization and targeting
of Aβ oligomers to the PSD. Aβ oligomers are highly associated with the PSD in AD hippocampal synapses, but are absent at NDAN synapses.
This key difference could likely be due to the levels and regulation of synaptic Zn2+, resulting in synaptic dysfunction and cognitive decline in AD
and preserved synapses and cognition in NDAN cases.
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their toxic effect, allowing synapses to remain functional.
The absence of oligomers at the PSD in the NDAN
samples may thus indicate that synaptic integrity is pre-
served in these individuals. Indeed, in this study we
found that levels of neuronal pCREB, a transcription fac-
tor required for proper synaptic plasticity and memory
function [57], were unchanged in NDAN as compared
to age-matched controls. Conversely, neuronal pCREB
levels were significantly decreased in both the CA3 and
DG in the AD hippocampus as compared to age-
matched normal individuals or NDAN (Figure 3). As
pCREB is essential for synaptic function, these results
further the notion that synaptic functional integrity is
preserved in NDAN cases, perhaps consequent to the
lack of synaptic Aβ oligomers.
The absence of Aβ oligomers at the PSD in NDAN
hippocampi indicates the existence of mechanisms that
actively target Aβ oligomers to the synaptic compart-
ment and suggests that such mechanisms are impaired
or absent in these cognitively-intact individuals. Among
possible others, the regulation of synaptic Zn2+ could be
a likely candidate mechanism. Indeed, the most signifi-
cant findings suggesting that Zn2+ regulation may be
such a factor in AD, is the reported coordination,
stabilization, and synaptic targeting of Aβ oligomers byZn2+ [25,26,43] along with increased Zn2+ levels and
decreased ZnT3 mRNA and protein expression in the
AD brain [27-30,32]. In addition, the coordination of
Zn2+ with Aβ (which potentially reduces Zn2+ availability
to target receptors and channels) produces a Zn2+ defi-
cient condition, which also causes synaptic dysfunction
[19]. Therefore, a double insult is produced; increased
synaptic targeting along with decreased Zn2+ signaling.
Consistent with previous reports [27-29], we found
that the total Zn2+ levels were increased in the AD sam-
ples (Figure 4A). We further found that the Zn2+ levels
in the soluble fraction from NDAN samples were signifi-
cantly lower than in AD samples, albeit higher than con-
trol. This latter result is not unexpected if one considers
that amyloid plaques are enriched in Zn2+ and other
metals [58,59]. The neuropathological analysis of NDAN
brains showed that the plaque load was comparable to
the AD samples and therefore the decreased Zn2+ levels
in NDAN suggest that there is a mechanism capable of
lowering levels of free Zn2+ and perhaps limiting the
Zn2+ available to coordinate with Aβ and target it to the
PSD.
The main storage area in the brain for Zn2+ that is not
bound to proteins is synaptic vesicles [54]. The Zn2+ in
these vesicles may be released along with glutamate fol-
lowing presynaptic depolarization and then interact with
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membrane. Synaptically released Zn2+ affects the mo-
lecular behavior of ambient Aβ oligomers [25]. There-
fore, the measurement of the vesicular Zn2+ pool
provides a better understanding of Zn2+ regulation and
homeostasis in AD. We found that synaptic vesicle Zn2+
concentrations were increased in AD and NDAN com-
pared to control (Figure 4B). Increased vesicular Zn2+ in
both AD and NDAN, along with reduced Zn2+ in the
soluble fractions from NDAN as compared to AD, sug-
gests the existence of a compensatory mechanism in
NDAN to remove excess Zn2+.
Indeed, we found that the expression of the synaptic
vesicle-specific Zn2+ transporter ZnT3 was preserved in
NDAN samples at levels comparable to those observed
in age-matched control cases. While our results confirm
lower ZnT3 levels in AD (Figure 4C), preserved levels of
ZnT3 and elevated vesicle Zn2+ in NDAN may represent
a mechanism that contain the extent of dysregulation of
Zn2+ homeostasis in the brain. Such regulation of Zn2+
may limit the targeting of Aβ oligomers to the postsy-
napse in NDAN, allowing for proper synaptic function
and resilience to cognitive decline.
A wealth of experimental evidence strongly suggests
that keeping the Aβ oligomers from associating with the
synapses would reduce synaptic dysfunction and thus
represent a valid approach to preserve cognitive integrity
despite the presence of Aβ in the CNS of diseased indi-
viduals. Here we have shown for the first time that indi-
viduals who have significant neuropathologic features of
AD, but who are cognitive intact, do not have LMW Aβ
oligomers associated with the postsynapse along with
evidence of a better preserved synaptic Zn2+ homeostasis
as compared to demented AD subjects. Taken together,
our results thus suggest that efficient synaptic Zn2+
regulation and lack of Aβ oligomers at the PSD may
contribute to preserving cognitive integrity despite the
presence of AD neuropathology.
However, while indicating a central role for synaptic
Zn2+ regulation, our present results do not exclude that
other mechanisms may contribute to the ability of the
PSD to resist Aβ oligomer binding in the NDAN brain.
To that end, it is worth noting recent evidence suggest-
ing that sustaining insulin signaling may prevent Aβ
oligomer binding to synaptic spines in cultured neurons
[56], and ongoing studies in our laboratory are investi-
gating whether such mechanisms may be also at play in
the NDAN brain. Further characterization of the NDAN
population may thus reveal additional details about the
collective mechanism(s) by which the human brain can
effectively resist the synaptic targeting of Aβ oligomers;
it is prudent to argue that such mechanism(s) will repre-
sent a valid therapeutic target for cognitive preservation
in the context of the pathologic processes of AD.Methods
Case subjects
Frozen mid-hippocampus tissue was obtained from the
Oregon Brain Bank at Oregon Health and Science Uni-
versity (OHSU) in Portland, OR (See Table 1). Donor
subjects were enrolled and clinically evaluated in studies
at the NIH-sponsored Layton Aging and AD Center
(ADC) at OHSU. Subjects were participants in brain
aging studies at the ADC and received annual neuro-
logical and neuropsychological evaluations, with a clin-
ical dementia rating (CDR) assigned by an experienced
clinician. Controls had normal cognitive and functional
examinations. The AD subjects were diagnosed by a
clinical team consensus conference, met the National In-
stitute for Neurological and Communicative Disorders
and Stroke-Alzheimer’s Disease and Related Disorder
Association diagnostic criteria for clinical AD, had a
CDR of greater than 1.0, and neuropathologic confirm-
ation at autopsy (after informed consent). Tissue use
conformed to institutional review board-approved proto-
cols. Neuropathologic assessment conformed to National
Institute on Aging-Reagan consensus criteria. All brain
tissue was examined by a neuropathologist for neurode-
generative pathology including neurofibrillary tangles
and neuritic plaques. Using standardized CERAD criteria
[60], cases were assigned an amyloid score based on the
deposition of amyloid plaques in the brain (0 = no pla-
ques, 1 = sparse plaques, 2 =moderate plaques, and
3 = dense plaques), and a Braak stage (0–6; with 6 being
the most severe) indicative of the level and location of
hyper-phosphorylated tau tangles [3]. In addition to the
pathological information detailed above, demographical
data were received along with the frozen tissue. These
included age, sex, and MMSE score [61] for each case.
To ensure that the variations in postmortem interval
(PMI) did not affect the measurements, a correlation
analysis between PMI values and results obtained in the
various assays presented here was performed using a
Pearson’s correlation test. No correlation was found for
any of the experiments presented (Additional File 2),
and therefore observed differences could not be attribu-
ted to differences in non-specific postmortem tissue deg-
radation among the various groups.
Immunohistochemistry
Five-mm sections of the mid hippocampus were brought
out of storage at −80°C and equilibrated to −20°C before
embedding in Tissue-Tek O.C.T. compound (Sakura
Finetek, Torrence, CA, USA). Ten μm sections were cut
and affixed to Superfrost Plus slides (Thermo Fisher Sci-
entific, Waltham, MA, USA), for further storage as
needed at −80°C. After equilibrating to room
temperature, sections were rinsed in 0.1 M PBS and then
fixed in ice-cold 4% paraformaldehyde for 15 min.
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blocking and permeabilization for 1 h in 0.1 M PBS con-
taining 10% goat serum, 0.03% Triton-X, and 0.1% phos-
phatase inhibitor (Thermo Fisher Scientific). Incubation
with the primary antibodies, 4 G8 (for Aβ from Covance,
Princeton Township, NJ, USA), phosphorylated tau (Ser
202, Pierce Biotechnology, Rockford, IL, USA) CREB,
phosphorylated CREB (Ser 133) and NeuN (Millipore,
Billerica, MA, USA), in 0.1 M PBS containing 10%
serum and 0.1% phosphatase inhibitor was carried out
overnight at room temperature. Following washing,
slides were incubated for 1 h with Alexa Fluor secondary
antibodies (Invitrogen, Carlsbad, CA, USA) in 0.1 M
PBS containing 10% serum and 0.1% phosphatase inhibi-
tor. Slides were rinsed twice in PBS and once in distilled
water before a 10 min incubation with 0.3% Sudan Black
B (EMD Chemicals, Gibbstown, NJ, USA) in 70% etha-
nol to block lipofuscin autofluorescence [62]. After rins-
ing in distilled deionized water, Vectashield containing
4′,6-diamidino-2-phenylindole (DAPI) was applied (Vec-
tor Laboratories, Burlingame, CA, USA), and coverslips
were mounted and nail polish was used to seal the
edges.
Microscopy
High-resolution images (1024x1024 TIFF) were acquired
using a confocal laser-scanning module (Bio-Rad Radi-
ance 2000 with LaserSharp software, Hercules, CA,
USA) mounted on a Nikon E800 upright microscope.
For these analyses the 20x//0.75NA, 40x/0.95NA and
60x-oil/1.4NA objectives were used (Nikon, Melville,
NY, USA) Images were acquired with a blue diode and
krypton lasers of 488 nm and 568 nm excitation. Images
for comparisons were acquired with constant settings
for laser power, detector gain, amplification gain, and
offset.
Bielschowsky stain
The modified Bielschowsky stain was performed as
described previously as a component of the neuropatho-
logical assessment [60].
Aβ 1–42 ELISA assay
The soluble fraction used for this assay was generated
using 200–300 mg of mid-hippocampus. The tissue was
homogenized using a 1 ml syringe with a 20 gauge nee-
dle in 50 mM Tris–HCl buffer (pH= 7.6) with 0.01%
NP-40, 150 mM NaCl, 2 mM EDTA, 0.1% SDS, 1 mM
phenylmethylsulfonyl fluoride and protease inhibitor
cocktail (Sigma-Aldrich, St. Louis, MO, USA). The hom-
ogenate was centrifuged for 5 min at 3000 rpm at 4°C
and the supernatant collected for analysis [10]. Samples
were normalized for protein content and diluted 1:100
in Standard Diluent Buffer provided in the ELISA kit(Invitrogen). The ELISA was performed according to the
manufacturer’s directions. All samples were measured in
duplicate at 450 nm.
Generation of Aβ oligomers
To prepare oligomeric Aβ, lyophilized Aβ aliquots
(0.3 mg) were dissolved in 0.2 ml 1,1,1,3,3,3-hexafluoro-
2-propanol (HFP) and then added to 0.7 ml H2O in
Eppendorf tubes. Tubes were loosely capped and sam-
ples stirred on a magnetic stirrer under a fume hood for
48 h and then used within 36 h. Quality of Aβ prepara-
tions was routinely checked by Western blot employing
both NU4 and 6E10 antibodies.
Synaptic Fractionation
Synaptic fractionation was performed as described previ-
ously [50,63]. Briefly, hippocampal tissue was homoge-
nized using a ground glass homogenizer and
synaptosomes were isolated using a sucrose gradient and
ultracentrifugation (100,000 x g for 3 h at 4°C). Synaptic
junctions were obtained by incubating the synaptosomes
in pH= 6 buffer (1 M Tris in 0.1 mM CaCl2) and then
centrifuging at 40, 000 x g for 30 min at 4°C. The super-
natant (containing synaptic vesicles) and the pellet were
collected separately. The pellet was solublized and incu-
bated in pH= 8 buffer (20 mM Tris, 1% Triton X-100 in
0.1 mM CaCl2) and then centrifuged at 40,000 x g for
30 min at 4°C to generate the PSD pellet. This pellet was
solublized in 1% SDS. The supernatant containing the
synaptic vesicles was concentrated using the 50 k cut-off
Ampicon centrifugation tubes from Millipore followed
by precipitation using acetone and then solublized in 1%
SDS.
Immunoblotting
Primary antibodies used were synaptophysin (Millipore),
PSD95 (Cell Signaling, Danvers, MA, USA), and ZnT3
(LifeSpan Biosciences, Seattle, WA, USA) The monoclo-
nal antibody 6e10 from Covance was used to detect Aβ.
The Aβ oligomer-specific antibody, NU4 (a gift from the
laboratory of William L. Klein), was used to detect
LMW oligomers. Ponceau S staining of the membranes
was performed to ensure equal protein loading before
incubation with antibodies. In addition, tubulin or
GAPDH (Cell Signaling) was used as a loading control.
After incubation with appropriate HRP-conjugated
(Sigma-Aldrich) or fluorescent secondary antibody
(1:10,000) (LI-COR Biosciences, Lincoln, NE, USA), the
membrane was either imaged after ECL incubation or
scanned directly by an Odyssey infrared fluorescent im-
aging system (LI-COR Biosciences). Band densities were
analyzed using Quantity One (Bio-Rad) or Odyssey soft-
ware and normalized using the measured loading control
densities. Each group was represented on each blot.
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one-way ANOVA followed by Tukey post-hoc analysis.
Different loading controls were utilized depending on
the sample fraction. This approach was necessary be-
cause many housekeeping proteins such as tubulin and
GAPDH have altered expression and localization in
aging and AD [64,65]. A variety of housekeeping pro-
teins and total protein stains [66] were tested in prelim-
inary experiments to determine the most appropriate
loading control for each fraction. The loading control
whose levels did not change depending on disease state
was used for that particular protein fraction.
Methods for the analysis of Zn2+
All laboratory processing was performed under clean
contaminant free conditions, to minimize external metal
contamination. Each sample was evaporated to dryness
in a drying oven at 80 0 C. Digestion of the residue was
carried out with a well established procedure [67] using
0.5 mL of 30% hydrogen peroxide (GFS Chemicals,
Powell, OH, USA) at 70 0 C for 18–24 h followed by
0.10 mL of Ultra-pure nitric acid (GFS Chemicals) until
completely ashed. The digested white ash was dissolved
in 4.0 mL of Milli-Q deionized distilled water. Each
digested sample was further suitably diluted 1:20, 1:40,
1:50, 1:80, 1:100 or 1:200 (v/v) using Milli-Q deionized
distilled water prior to analysis.
Concentrations of Zn2+ in the diluted digested samples
were determined by GF-AAS as described previously
[63]. A Varian Instruments Model-240Z Zeeman atomic
absorption spectrophotometer (Varian, Inc., Walnut
Creek, CA, USA) equipped with a Varian GTA-120
graphite tube analyzer, a PSD-120 programmable sample
dispenser, a Varian UltrAA high intensity boosted hollow
cathode lamp were routinely used to measure Zn2+ at
low parts per billion (ppb) levels in solution. Pyrolytically
coated Varian graphite partition tubes were used for all
GF-AAS analyses. Argon gas (0.3 L/min flow) was used
to protect and purge the graphite tubes during the fur-
nace program steps, and the data acquisitions were car-
ried out using Varian SpectrAA software.
The auto-sampler cups were washed initially with
0.5 N Ultra-pure nitric acid followed by Milli-Q deio-
nized distilled water prior to use. Calibration standards
(0.0, 0.5, 1.0, 1.5, and 2.0 micrograms per liter (ppb)) of
Zn2+ were prepared in Milli-Q deionized distilled water
and run with each set of samples and the absorbance
was measured at 213.9 nm wavelength. Precision and ac-
curacy of the method were routinely checked by digest-
ing known weights of SRM1577a standard liver powder
(NIST, Bethesda, MD, USA) and analyzing them rou-
tinely along with these samples. These liver powders
contain known certified amounts of several metals in-
cluding Zn2+.Data collection and statistical analysis
For immunohistochemistry, analysis was performed with
ImageJ (NIH) and a set of plug-ins developed by Wright
Cell Imaging Facility (http://www.uhnres.utoronto.ca/fa-
cilities/wcif/imagej/). Two images per region (DG and
CA3) were analyzed for each clinical case. A blind coun-
ter quantified the number of neurons in the field of
view, and how many of these exhibited robust nuclear
pCREB immunoreactivity. This value is expressed as the
percentage of neurons that are pCREB positive. Micro-
soft Excel was used for graph production and StatPlus or
Sigmaplot were used for data analysis. One-way ANOVA
with a Fisher post hoc test was used to determine statis-
tical significance. If the data failed the normality test
(Shapiro-Wilk), a Bonferroni correction was made before
statistical analysis. Data represents mean ± SEM.Additional files
Additional file 1: Phosphorylated CREB levels are not significantly
altered when detected by Western blot in hippocampal total
homogenates. (A) Representative Western blot of total and
phosphorylated CREB in hippocampal total homogenate fractions
prepared from control, AD and NDAN cases. Densitometric analysis
shown in (B) revealed only a trend of reduced pCREB levels in the AD
samples, which however did not reach statistical significance (ANOVA,
p> 0.05); n = 6 per group.
Additional file 2: Variability in postmortem interval does not
correlate with differences in protein and Zn2+ measurements
performed. Abbreviations are as follows; SF – soluble fraction, PSD –
postsynaptic density, and SV – synaptic vesicles. A Pearson correlation
test was preformed for each measurement against the postmortem
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